DOI: 10.1055/s-00000054

Pharmacopsychiatry

Issue 07 · Volume 47 · November 2014 DOI: 10.1055/s-004-28008

Review

231
Veerman, S. R. T.; Schulte, P. F. J.; Begemann, M. J. H.; de Haan, L.: Non-Glutamatergic Clozapine Augmentation Strategies: A Review and Meta-Analysis

Original Paper

239
Wenzel-Seifert, K.; Brandl, R.; Hiemke, C.; Haen, E.: Influence of Concomitant Medications on the Total Clearance and the Risk for Supra-therapeutic Plasma Concentrations of Citalopram. A Population-Based Cohort Study
245
Proft, F.; Kopf, J.; Olmes, D.; Hempel, S.; Schmidt, B.; Riederer, P.; Deckert, J.; Pfuhlmann, B.; Reif, A.; Unterecker, S.: SLC6A2 and SLC6A4 Variants interact with Venlafaxine Serum Concentrations to Influence Therapy Outcome
251
Saleh, M. I.: Modeling Longitudinal Changes in Buprenorphine Treatment Outcome for Opioid Dependence
259
Tarumi, R.; Suzuki, T.; Tani, H.; Den, R.; Sawada, N.; Sakurai, H.; Tsutsumi-Ozawa, C.; Ohtani, A.; Mimura, M.; Uchida, H.: Timing of Adjunctive Therapy in the Treatment of Depression: A Chart Review
263
Leung, J. G.; Chengappa, K. N. R.; Ivanov, E.; Gandotra, G.; Kahn, C. E.; Weber, J. S.; Fabian, T. J.: Antipsychotic Agents used to Augment Clozapine during Long-Term Inpatient Hospitalizations

Letter

268
Grunze, H.; Walden, J.: Katayama et al.: Therapeutic Window of Lamotrigine for Mood Disorders: A Naturalistic Retrospective Study. Pharmacopsychiatry 2014; 47: 111–114
270
Terao, T.; Katayama, Y.; Kamei, K.: Reply to the Letter from Grunze and Walden